Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1
NCT ID: NCT00032929
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
269 participants
INTERVENTIONAL
2001-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Selegiline in Treatment of Cocaine Dependence - 2
NCT00000188
Selegiline in Outpatient Treatment for Cocaine Dependence - 1
NCT00000336
Infusion Laboratory: Protocol 1 - Selegeline - 2
NCT00000337
Pharmacological Modulation of Cocaine Effects - 1
NCT00000201
Modafinil Treatment for Cocaine-Dependent Individuals
NCT00129285
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Selegiline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
* DSM-4 diagnosis of cocaine dependence
* Ability to understand and provide written consent
* Female subjects must use acceptable birth control
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Somerset Pharmaceuticals
INDUSTRY
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
National Institute on Drug Abuse
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Elkashef, MD
Role: STUDY_CHAIR
National Institute on Drug Abuse (NIDA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson VA Medical Center
Tucson, Arizona, United States
Haight-Ashbury Free Clinic
Berkeley, California, United States
Friends Research Institute-2
Los Angeles, California, United States
Friends Research Institute
Los Angeles, California, United States
San Francisco General Hosptial
San Francisco, California, United States
San Francisco VA Medical Center
San Francisco, California, United States
Denver VA Medical Center
Denver, Colorado, United States
New Orleans VA Medical Center
New Orleans, Louisiana, United States
VA Maryland Healthcare System
Baltimore, Maryland, United States
Wayne State University
Detroit, Michigan, United States
Cincinnati VA Medical Center
Cincinnati, Ohio, United States
Medical University of South Carolina
Charleston, South Carolina, United States
VA North Texas Health Care System
Dallas, Texas, United States
University of Texas Hlth Sci Ctr Houston
Houston, Texas, United States
Salt Lake City VA Medical Center
Salt Lake City, Utah, United States
VA Puget Sound Health Care System
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Elkashef A, Fudala PJ, Gorgon L, Li SH, Kahn R, Chiang N, Vocci F, Collins J, Jones K, Boardman K, Sather M. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend. 2006 Dec 1;85(3):191-7. doi: 10.1016/j.drugalcdep.2006.04.010. Epub 2006 May 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-CSP-1019-1
Identifier Type: -
Identifier Source: org_study_id
NCT00007553
Identifier Type: -
Identifier Source: nct_alias
NCT00024700
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.